Isoflurane Piramal (Isoflurane)

Isoflurane is an inhalational anesthetic used in the management of peri‑operative anesthesia.

• Induction of general anesthesia: rapid onset of unconsciousness and analgesia to facilitate endotracheal intubation and surgical start.
• Maintenance of general anesthesia: continuous delivery maintains a stable anesthetic plane, allowing controlled ventilation and hemodynamic stability during operations.
• Procedural sedation: provides deep sedation for brief diagnostic or interventional procedures when a full general anesthetic is not required.
• Emergency airway management: facilitates rapid sequence induction and airway control in emergency settings.

• Isoflurane produces anesthesia by potentiating the inhibitory neurotransmitter γ‑aminobutyric acid (GABA) at the GABA_A receptor complex, enhancing chloride influx and hyperpolarizing neuronal membranes. It also reduces excitatory NMDA receptor activity and depresses neuronal firing in the thalamus and cerebral cortex, leading to loss of consciousness, analgesia, and muscle relaxation. These actions collectively suppress synaptic transmission throughout the central nervous system, producing the clinical anesthetic state.

Isoflurane may be associated with a range of adverse reactions, varying from mild to severe.

Common Side Effects

• Airway irritation: coughing or breathlessness during induction.
• Hypotension: transient drop in blood pressure due to vasodilation.
• Nausea and vomiting: postoperative emesis.
• Dry mouth: reduced salivation.
• Headache: mild to moderate headache during recovery.
• Drowsiness: excessive sleepiness post‑operatively.
• Shivering: postoperative muscle tremors.
• Hypoxia: transient low oxygen saturation during emergence.
• Taste disturbance: metallic or unpleasant taste during inhalation.

Serious or Rare Side Effects

• Malignant hyperthermia: life‑threatening hypermetabolic crisis triggered in susceptible individuals.
• Arrhythmias: cardiac rhythm disturbances, including ventricular ectopy.
• Hepatotoxicity: rare liver enzyme elevation or injury.
• Respiratory depression: severe reduction in ventilation requiring support.
• Seizures: rare occurrence in predisposed patients.

When using Isoflurane, clinicians should observe specific precautions to ensure patient safety and drug integrity.

• Patient assessment: evaluate cardiovascular and respiratory status before administration.
• Monitoring: continuously monitor blood pressure, heart rate, oxygen saturation, and end‑tidal anesthetic concentration.
• Contraindications: avoid use in patients with known malignant hyperthermia susceptibility.
• Drug interactions: adjust dosage when combined with other central nervous system depressants.
• Environmental safety: ensure proper scavenging systems to limit occupational exposure.
• Store at ambient temperature: keep the solution in original container, protect from light and moisture, and store below 25 °C.

Isoflurane can interact with other agents, influencing anesthetic depth or patient physiology.

Major Interactions (Avoid)

• Potent CYP2E1 inducers (e.g., rifampin, carbamazepine): may increase hepatic metabolism of isoflurane, leading to a reduced anesthetic effect and the need for higher vaporizer settings.
• Chronic alcohol consumption: can alter isoflurane pharmacodynamics, potentially increasing hepatic stress and modifying the required anesthetic concentration.
• Neuromuscular blocking agents (e.g., rocuronium, vecuronium): may potentiate muscle relaxation when combined with isoflurane, necessitating careful dose titration to avoid prolonged paralysis.

Moderate Interactions (Monitor Closely)

• Co‑administration with other inhalational anesthetics (e.g., sevoflurane, desflurane): additive central nervous system depression may require lower combined concentrations to maintain appropriate depth.
• Opioids (e.g., fentanyl, morphine): synergistic analgesic effects can enhance respiratory depression, so ventilation parameters should be closely observed.
• Beta‑blockers (e.g., propranolol, metoprolol): may exaggerate the hypotensive response produced by isoflurane, warranting vigilant blood pressure monitoring.